We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current SHJBF market cap is 407.89M. The company's latest EPS is CNY -10.4126 and P/E is -0.18.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 767.79M | 1.59B | 4.02B | 1.44B | 1.48B |
| Operating Income | 677.11M | 1.21B | 2.77B | 938.77M | 941.87M |
| Net Income | -747.42M | -1.67B | -720.91M | -2.39B | -2.28B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 4.41B | 8B | 11.03B | 12.56B | 11.34B |
| Total Liabilities | 1.43B | 2.17B | 2.72B | 2.78B | 4.02B |
| Total Equity | 2.98B | 5.83B | 8.32B | 9.78B | 7.32B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | -1.18B | -1.46B | -605.05M | -1.78B | -2B |
| Investing | -959.59M | -740.41M | -1.92B | -437.21M | -933.19M |
| Financing | 593.58M | 4.41B | 2.67B | 4.61B | 711.83M |
| Market Cap | 407.89M |
| Price to Earnings Ratio | -0.18 |
| Price to Sales Ratio | 0.28 |
| Price to Cash Ratio | 0.11 |
| Price to Book Ratio | 0.06 |
| Dividend Yield | - |
| Shares Outstanding | 219.3M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -13.49% |
| 52 Week High | 2.15 |
| 52 Week Low | 0.9524 |
| Spread (Intraday) | 50k (100%) |
| Company Name | Shanghai Junshi Biosciences Company Ltd (PK) |
| Address |
shanghai 200126 |
| Website | https://www.junshipharma.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
